Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Научный центр психического здоровья РАМН, Москва
Список исп. литературыСкрыть список 1. Александровский Ю.А., Краснов В.Н., Незнанов Н.Г., Ромасенко Л.В. Эффективность этифоксина в сравнении с феназепамом при лечении пациентов с расстройствами адаптации (открытое рандомизированное контролируемое исследование). Рос. психиатрич. журн. 2010; 1: 74–8. 2. Андрющенко А.В., Бескова Д.А., Романов Д.В. Психофармакотерапия генерализованной тревоги (опыт применения Стрезама и Атаракса). Психич. расстройст. в общ. мед. 2010; 1: 33–6. 3. Арана Д., Розенбаум Д. Руководство по психофармакотерапии. М., 2001. 4. Воронина Т.А., Середенин С.Б. Перспективы поиска новых анксиолитиков. Экспер. и клин. фармакол. 2002; 5: 4–17. 5. Мосолов С.Н. Основы психофармакотерапии. М., 1996. 6. Смулевич А.Б., Дробижев М.Ю., Иванов С.В. Клинические эффекты бензодиазепиновых транквилизаторов в психиатрии и общей медицине. М., 2005. 7. Alonso J, Angermeyer MC, Bernert S et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand 2004; 109 (Suppl. 429): 21–7. 8. Anssea M, Dierick M, Buntinkx F et al. High prevalence of mental disorders in primary care. J Affect Disord 2004; 78 (1): 49–55. 9. Boissier JR, Simon P, Zaczinska M, Fichelle J. Experimental psychopharmacologic study of a new psychotropic drug, 2-ethylamino-6-chloro-4-methyl-4-phenyl-4H-3,1-benzoxazine. Therapie 1972; 27 (2): 325–38. 10. Culpepper L. Effective Recognition and Treatment of Generalized Anxiety Disorder in Primary Care. Prim Care Companion J Clin Psychiatry 2004; 6 (1): 35–41. 11. Demyttenaere K, Bruffaerts R, Posada-Villa J et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. WHO World Mental Health Survey Consortium. JAMA 2004; 291 (21): 2581–90. 12. Dowson C, Laing R, Barraclough R et al. The use of the Hospital Anxiety and Depression Scale (HADS) in patients with chronic obstructive pulmonary disease: a pilot study. N Z Med J 2001; 114 (1141): 447–9. 13. Hamon A, Morel A, Hue B et al. The modulatory effects of the anxiolytic etifoxine on GABAA receptors are mediated by the b-subunit. Neuropharmacology 2003; 45: 293–303. 14. Jackson JL, Houston JS, Hanling SR et al. Clinical Predictors of Mental Disorders Among Medical Outpatients. Arch Intern Med 2001; 161: 875–9. 15. Jefferies K, Owino A, Rickards H et al. Psychiatric disorders in inpatients on a neurology ward: estimate of prevalence and usefulness of creening questionnaires. J Neurol Neurosurg Psychiatry 2007; 78: 414–6. 16. Kessler RC, Berglund P, Demler O et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593–602. 17. Marchesi C, Brusamonti E, Borghi C et al. Anxiety and depressive disorders in an emergency department ward of a general hospital: a control study Emerg Med J 2004; 21: 175–9. 18. Micallef J, Soubrouillard C, Guet F et al. A double blind parallel group placebo controlled comparison of sedative and mnesic effects of etifoxine and lorazepam in healthy subjects. Fundam Clin Pharmacol 2001; 15: 209–16. 19. Miovic M, Block S. Psychiatric disorders in advanced cancer. Cancer 2007; 110 (8): 1665–76. 20. Nandi A, Beard JR, Galea S. Epidemiologic heterogeneity of common mood and anxiety disorders over the lifecourse in the general population: a systematic review. BMC Psychiatry 2009; 9: 31. 21. Nguyen N, Fakra E, Pradel V et al. Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice. Hum Psychopharmacol 2006; 21 (3): 139–49. 22. Olfson M, Fireman B, Weissman MM et al. Mental disorders and disability among patients in a primary care group practice. Am J Psychiatry 1997; 154 (12): 1734–40. 23. Schlichter R, Rybalchenko V, Poisbeau P et al. Modulation of GABAergic synaptic transmission by the non-benzodiazepine anxiolytic etifoxine. Neuropharmacology 2000; 39: 1523–35. 24. Servant D, Graziani PL, Moyse D et al. Traitement du trouble de l’adaptation avec anxiete: evaluation de l’efficacite et de la tolerance de l’etifoxine par un essai en double aveugle contre produit de reference. L’Encep Hale 1998; 24: 569–74. 25. Stark D, Kiely M, Smith A et al. Anxiety disorders in cancer patients: their nature, associations, and relation to quality of life. J Clin Oncol 2002; 20 (14): 3137–48. 26. Toft T, Fink P, Oernboel E et al. Mental disorders in primary care: prevalence and co-morbidity among disorders. results from the functional illness in primary care (FIP) study. Psychol Med 2005; 35 (8): 1175–84. 27. Verleye M, Schlichter R, Gillardin JM. Interaction of etifoxine with the chloride channel coupled to the GABAA receptor complex. Neuroreport 1999; 10: 3207–10. 28. Verleye M, Schlichter R, Neliat G et al. Functional modulation of gamma-amino acid A receptor by etifoxine and allopregnanolone in rodents. Neuroscience Letters 2001; 301: 191–4. 29. Verleye M, Pansart Y, Gillardin JM. Effects of etifoxine on ligand binding to GABAA receptors in rodents. Neuroscience Research 2002; 44: 167–72. 30. Verleye M, Gillardin JM. Effects of etifoxine on stress-induced hyperthermia, freezing behavior and colonic motor activation in rats. Physiol Behav 2004; 82 (5): 891–7. 31. Weiser EB. The Prevalence of Anxiety Disorders Among Adults with Asthma: A Meta-Analytic Review. J Clin Psychol Med Settings 2007; 14 (4): 297–307. 32. Welfel ER, Ingersoll RE. Counseling for Adjustment Disorders and Life Stress. In The mental health desk reference. New Jersey, 2001.